

Notice of Annual General Meeting – Poolbeg Pharma plc

Notice is hereby given that the annual general meeting (“AGM”) of Poolbeg Pharma plc (“Company”) will be held at the offices of Gravita at Aldgate Tower, 2 Leaman Street, London, E1 8FA on 9 June 2026 at 12 noon for the purposes of considering and voting on the resolutions below. Resolutions 1 to 11 will be proposed as ordinary resolutions and Resolutions 12 and 13 will be proposed as special resolutions. Relevant documentation can also be consulted on the Investors section of the Company’s website.

Ordinary Business

Resolution 1

THAT the Audited Accounts for the 12 months ended 31 December 2025, together with the Directors’ Report and Auditors’ Report thereon, be received and adopted.

Resolution 2

THAT Gravita Audit II Limited be re-appointed as auditors of the Company to hold office from the conclusion of the AGM until the conclusion of the next annual general meeting at which accounts are laid before the Company.

Resolution 3

THAT the audit committee of the Company (“Audit Committee”) be authorised to agree the remuneration of Gravita Audit II Limited as auditors of the Company.

Resolution 4

THAT the Directors’ Remuneration Report set out in the Company’s annual report and accounts for the year ended 31 December 2025 be approved.

Resolution 5

THAT Professor Brendan Buckley be re-elected as a Director of the Company.

Resolution 6

THAT Professor Luke O’Neill be re-elected as a Director of the Company.

Resolution 7

THAT Dr Jeremy Skillington be re-elected as a Director of the Company.

Resolution 8

THAT Ian O’Connell be re-elected as a Director of the Company.

Resolution 9

THAT Dr Eddie Gibson be re-elected as a Director of the Company.

Resolution 10

THAT Cathal Friel be re-elected as a Director of the Company.

Resolution 11

THAT in accordance with the requirements of section 551 of the Companies Act 2006 (“Act”), and in substitution for any existing authority (but without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such authority), the Directors be and they are hereby generally and unconditionally authorised to exercise all powers of the Company to allot Relevant Securities (as defined in the note to this Resolution):

Notice of Annual General Meeting (continued)

11.1 comprising equity securities (as defined by section 560 of the Act) up to an aggregated nominal amount of £35,255 (176,275,000 new ordinary shares in the capital of the Company) (such amount to be reduced by the nominal amount of any Relevant Securities allotted pursuant to the authority in paragraph 11.2 below) in connection with a fully pre-emptive offer:

- a) to holders of ordinary shares in proportion (as nearly as may be practicable) to their respective holdings; and
- b) to holders of other equity securities as required by the rights of those securities or as the Directors otherwise consider necessary,

but subject to such exclusions or other arrangement as the Directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates, legal or practical problems in or under the laws of any territory or the requirements of any regulatory body or stock exchange; and

11.2 in any other case, up to a maximum aggregate nominal amount of £35,255 (176,275,000 new ordinary shares in the capital of the Company) (such amount to be reduced by the nominal amount of any equity securities allotted pursuant to the authority in paragraph 11.1 above),

PROVIDED that such authority shall expire on the earlier of (i) the conclusion of the annual general meeting of the Company to be held in 2027; and (ii) the date falling 15 months from the date of the passing of this Resolution, unless any such authorities are renewed, varied or revoked by the Company prior to or on that date and provided also that the Company may, before such expiry, make an offer or agreement which would or might require shares in the Company or rights to be allotted or granted after such expiry and the Directors may allot shares in the Company or grant rights pursuant to any such offer or agreement as if the authority conferred by this Resolution had not expired.

Special Business

Resolution 12

THAT, subject to Resolution 11 being passed, and in substitution for any existing authority (but without prejudice to the authority conferred pursuant to Resolution 13), the Directors be generally and unconditionally authorised in accordance with section 570(1) of the Act to exercise all the powers of the Company to allot equity securities for cash and grant rights to subscribe for, or to convert any security into, equity securities in connection with:

12.1 an offer of equity securities (as defined by section 560 of the Act) (but, in the case of the authority granted under Resolution 11.1, by way of a fully pre-emptive offer only):

- a) to the holders of ordinary shares in proportion (as nearly as may be practicable) to their respective holdings; and
- b) to holders of other equity securities as required by the rights of those securities or as the Directors otherwise consider necessary,

but subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates, legal or practical problems in or under the laws of any territory or the requirements of any regulatory body or stock exchange;

12.2 the allotment of equity securities (as defined by section 560 of the Act) (otherwise than pursuant to paragraph 12.1 of this Resolution) to any person up to a maximum aggregate nominal amount of £14,102; and

12.3 the allotment of equity securities (as defined in section 560 of the Act) (otherwise than pursuant to paragraphs 12.1 or 12.2 of this resolution) to any person up to an aggregate nominal amount equal to 20% of any allotment of equity securities from time to time under paragraph 12.2 of this resolution, such power to be used only for the purposes of making a follow-on offer which the Directors determine to be of a kind contemplated by paragraph 3 of Part 2B of the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this Notice of AGM,

Notice of Annual General Meeting (continued)

PROVIDED ALSO that such power shall expire on the earlier of (i) the conclusion of the annual general meeting of the Company to be held in 2027; and (ii) the date falling 15 months from the date of the passing of this Resolution unless any such authorities are renewed, varied or revoked by the Company prior to or on that date and provided also that the Company may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted after such expiry, and the Directors may allot equity securities pursuant to any such offer or agreement as if such powers had not expired.

Resolution 13

THAT, subject to Resolution 11 being passed, in accordance with section 570(1) of the Act, and in substitution for any existing (but without prejudice to the authority conferred pursuant to Resolution 12), the Directors be and they are hereby empowered to allot equity securities (within the meaning of section 560 of the Act) for cash pursuant to the authorities conferred by Resolution 11 as if section 561 of the Act did not apply to such allotment, PROVIDED that this power shall be limited to the allotment of equity securities (as defined in section 560 of the Act):

- 13.1 up to an aggregate nominal amount of £14,102, such power only to be used for the purposes of financing (or refinancing if the power is to be used within 12 months after the original transaction) a transaction which the Directors determine to be either an acquisition or a specified capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this Notice of AGM; and
- 13.2 (otherwise than under paragraph 13.1 of this resolution) up to a nominal amount equal to 20% of any allotment of equity securities from time to time under paragraph 13.1 of this resolution, such power to be used only for the purposes of making a follow-on offer which the Directors determine to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this Notice of AGM,

PROVIDED ALSO that such power shall expire on the earlier of (i) the conclusion of the annual general meeting of the Company to be held in 2027; and (ii) the date falling 15 months from the date of the passing of this Resolution unless any such authorities are renewed, revoked or varied by the Company prior to or on that date and provided also that the Company may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted after such expiry, and the Directors may allot equity securities pursuant to any such offer or agreement as if such powers had not expired.

By order of the Board

BEACH SECRETARIES LIMITED

Company secretary

Registered office:-

40 Bank Street,
Floor 24
London
England,
E14 5NR

Registered number: 13279507

7 May 2026

Notice of Annual General Meeting (continued)

Explanatory Notes

Resolution 1

The Directors are required by law to lay the Audited Accounts and the Directors' Report and Auditors' Report for the 12 months ended 31 December 2025 before a general meeting of the Company. At the AGM, these documents will be presented to shareholders.

Resolution 2

The auditor is required to be re-appointed at each annual general meeting at which Audited Accounts are laid. The Directors, on the recommendation of the Audit Committee (which has evaluated the effectiveness and independence of the external auditors), are proposing the re-appointment of Gravita Audit II Limited as auditor.

Resolution 3

This resolution authorises the Audit Committee to agree the auditors' remuneration. It is considered best practice to provide for this authority in a separate resolution and not link it to the appointment of the auditors in Resolution 2.

Resolution 4

This resolution seeks shareholder approval of the Directors' Remuneration Report, as set out in the annual report and accounts for the year ended 31 December 2025. The vote is advisory only.

Resolutions 5 to 10

In accordance with the QCA Corporate Governance Code 2023 ("**2023 Code**"), all directors of companies should be subject to annual re-election. Resolutions 5 to 10 seek your approval to re-elect each of the Directors.

Biographical details of all of the Directors seeking re-election appear on the Company's investor website (<https://www.poolbegpharma.com/about/leadership/>). Having considered the performance of and the contribution made by each of the Directors, the Board is satisfied that the Directors' performance remains effective and that they each continue to demonstrate commitment to their roles.

Resolution 11

Subject to certain exceptions, the Directors may only issue new shares (and other Relevant Securities, as defined below) if authorised to do so by shareholders.

Resolution 11 is in two parts:

- (a) paragraph 11.1 would allow the Directors to issue new securities in relation to a rights issue or open offer. This authority would be limited to a maximum nominal amount of £35,255 (176,275,000 new ordinary shares in the capital of the Company), although that figure would be reduced by the nominal amount of any new securities issued under paragraph 11.2; and
- (b) paragraph 11.2 would allow the Directors to issue further new securities up to an additional maximum nominal amount of £35,255 (176,275,000 new ordinary shares in the capital of the Company) for any reason, although that figure would be reduced by the nominal amount of any new securities issued under paragraph 11.1.

The figure of £35,255 represents approximately 25% of the Company's issued ordinary shares as at 30 April 2026, the latest practicable date prior to publication of this Notice of AGM.

The authority granted under this resolution will expire on the earlier of (i) the conclusion of the annual general meeting of the Company to be held in 2027, and (ii) the date falling 15 months from the date of the passing of this Resolution, unless any such authorities are renewed, varied or revoked by the Company prior to or on that date.

Notice of Annual General Meeting (continued)

In Resolution 11, **Relevant Securities** means (i) shares in the Company, other than shares allotted pursuant to: (a) an employee share scheme (as defined in section 1166 of the Act); (b) a right to subscribe for shares in the Company where the grant of the right itself constitutes a Relevant Security; or (c) a right to convert securities into shares in the Company where the grant of the right itself constitute a Relevant Security; and (ii) any right to subscribe for or convert any securities into shares in the Company other than rights to subscribe for or convert any security into shares allotted pursuant to an employee share scheme (as defined in section 1166 of the Act). Reference to the allotment of Relevant Securities in Resolution 11 includes the grant of such rights.

Resolutions 12 and 13

Resolutions 12 and 13 seek to enable the Directors to allot equity securities (such as ordinary shares) in the Company for cash, without first offering those equity securities to existing shareholders in proportion to their existing holdings, and within the limits prescribed by the Statement of Principles on the Disapplication of Pre-emption Rights issued by the Pre-Emption Group.

In November 2022, the Pre-Emption Group revised its Statement of Principles on the Disapplication of Pre-emption Rights (the “**Principles**”). The revised Principles make a number of changes designed to improve capital raising processes for publicly traded companies by, among other matters, increasing the ‘routine’ disapplication thresholds and introducing new supplemental disapplication thresholds.

The Principles now provide that a company may seek power to issue, on a non-pre-emptive basis, shares for cash in any one year representing: (i) no more than 10% (previously 5%) of the company’s issued ordinary share capital for use in any circumstances; and (ii) no more than an additional 10% (previously 5%) of the company’s issued ordinary share capital provided that such additional power is only used in connection with an acquisition or specified capital investment which is announced contemporaneously with the issue, or which has taken place in the preceding 12 month period (previously 6 months) and is disclosed in the announcement of the issue.

The Principles also provide that, in both cases (i) and (ii) outlined above, a company may now seek a further power to issue, on a non-pre-emptive basis, shares for cash representing no more than 2% of the company’s issued ordinary share capital for the purposes of making a ‘follow-on’ offer (being an offer of a kind contemplated by the Principles) to certain retail investors and existing shareholders.

The Board has carefully considered the increased and supplemental thresholds available under the revised Principles, and has concluded that it is in the best interests of the Company and its shareholders to seek disapplication powers up to the higher 10% thresholds permitted and to seek specific disapplication powers in connection with ‘follow-on’ offers.

Accordingly, Resolution 12 is proposed as a special resolution. If this resolution is passed, it will permit the Board to allot ordinary shares for cash on a non-pre-emptive basis both in connection with a rights issue or similar pre-emptive issue and, otherwise than in connection with any such issue, up to a maximum nominal amount of £14,102. This amount represents 10% of the Company’s current issued share capital. This resolution will permit the Board to allot ordinary shares for cash on a non-pre-emptive basis, up to the specified level, in any circumstances. The resolution also seeks a further power over no more than 2% of the Company’s current issued share capital to be used only for the purposes of making a follow-on offer of a kind contemplated by the Principles.

Resolution 13 is proposed as a separate special resolution in line with best practice. If this resolution is passed, it will afford the Board an additional power to allot ordinary shares for cash on a non-pre-emptive basis up to a further maximum nominal amount of £14,102. This amount also represents 10% of the Company’s current issued share capital. The Board shall use the power conferred by this resolution only in connection with either an acquisition or a specified capital investment which is announced contemporaneously with the issue, or which has taken place in the preceding 12 month period and is disclosed in the announcement of the issue. The resolution also seeks a further power over no more than 2% of the Company’s current issued share capital to be used only for the purposes of making a follow-on offer of a kind contemplated by the Principles.

The Directors have no present intention of issuing any equity securities for cash pursuant to the disapplications proposed under Resolutions 12 and 13. The Board confirms that, if it does exercise these powers, it will follow the shareholder protections and features set out in Part 2B of the Principles.

Notice of Annual General Meeting (continued)

Corporate Governance

For information on the Company's corporate governance, the independence of the members of the Board and its committees and Poolbeg's Statement of Compliance in relation to the 2023 Code please refer to the Corporate Governance section of the Company's website: (<https://www.poolbegpharma.com/investors/corporate-governance/>)

Notice of Annual General Meeting (continued)

NOTES:

1. As a member of the Company who is entitled to attend and vote at the AGM, you are entitled to appoint one or more proxies to exercise all or any of your rights to attend, speak and vote at the AGM and you should have received a Form of Proxy with this Notice of AGM. You can only appoint a proxy using the procedures set out in these notes and the notes to the Form of Proxy. Appointment of a proxy does not preclude you from attending the AGM and voting in person. If you have appointed a proxy and attend the AGM in person, your proxy appointment will automatically be terminated.
2. A proxy does not need to be a member of the Company but must attend the AGM to represent you. Details of how to appoint the Chairman of the Meeting or another person as your proxy using the Form of Proxy are set out in the notes to the Form of Proxy. If you wish your proxy to speak on your behalf at the AGM you will need to appoint your own choice of proxy (not the Chairman) and give your instructions directly to them.
3. To appoint a proxy using the form accompanying this Notice of AGM, the Form of Proxy must be:
 - completed and signed;
 - sent or delivered to our Registrars, Equiniti, Highdown House, Yeoman Way, Worthing, BN99 6DA; or
 - scanned as a PDF file and sent by email to ProxyVotes@equiniti.com and
 - received by Equiniti no later than 12 noon on 5 June 2026.
4. In the case of a member which is a company, the Form of Proxy must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the Form of Proxy is signed (or a duly certified copy of such power or authority) must be included with the Form of Proxy.
5. A corporation which is a member can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a member provided that no more than one corporate representative exercises powers over the same share.
6. To change your proxy instructions, simply submit a new proxy appointment using the methods set out above. Note that the cut-off time for receipt of proxy appointments (see above) also applies in relation to amended instructions; any amended proxy appointment received after the relevant cut-off time will be disregarded.
7. In order to revoke a proxy instruction you will need to inform the Company by sending a signed hard copy notice clearly stating your intention to revoke your proxy appointment to our Registrars Equiniti, Highdown House, Yeoman Way, Worthing, BN99 6DA, to be received by the Company's Registrars no later than 12 noon on 5 June 2026. In the case of a member which is a company, the revocation notice must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the revocation notice is signed (or a duly certified copy of such power or authority) must be included with the revocation notice.
8. If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.
9. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so by using the procedures described in the CREST Manual. CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

Notice of Annual General Meeting (continued)

10. In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a “CREST Proxy Instruction”) must be properly authenticated in accordance with Euroclear UK & International Limited specifications, and must contain the information required for such instruction, as described in the CREST Manual (available via www.euroclear.com). The message, regardless of whether it constitutes the appointment of a proxy or is an amendment to the instruction given to a previously appointed proxy must, in order to be valid, be transmitted so as to be received by the Company’s agent (ID RA19) by 12 noon on 5 June 2026. For this purpose, the time of receipt will be taken to be the time (as determined by the time stamp applied to the message by the CREST Application Host) from which the Company’s agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.
11. CREST members and, where applicable, their CREST sponsors, or voting service providers should note that Euroclear UK & International Limited does not make available special procedures in CREST for any particular message. Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST sponsored member, or has appointed a voting service provider, to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting system providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.
12. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.
13. If you are an institutional investor you may be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your proxy must be lodged by 12 noon on 5 June 2026 in order to be considered valid. Before you can appoint a proxy via this process you will need to have agreed to Proxymity’s associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic appointment of your proxy
14. As at 30 April 2026 (being the last business day prior to the publication of this Notice of AGM) the Company’s issued share capital consists of 705,103,778 ordinary shares of 0.02 pence each carrying one vote each. The total voting rights in the Company as at close of business on 30 April 2026 are therefore 705,103,778.
15. Pursuant to regulation 41(1) of the Uncertificated Securities Regulations 2001 (2001 No. 3755) the Company has specified that only those members registered on the Register of Members of the Company at 18:30 on 5 June 2026 shall be entitled to attend and vote at the AGM in respect of the number of ordinary shares registered in their name at that time. Changes to the Register of Members after 18:30 on 5 June 2026 shall be disregarded in determining the rights of any person to attend and vote at the AGM.